Mercaptopurine

證據等級: L5

預測適應症: 10 個

Mercaptopurine: From Acute Lymphoblastic Leukemia to Myeloid Leukemia

One-Sentence Summary

Mercaptopurine (6-MP) is a purine antimetabolite classically established as the backbone of maintenance therapy for acute lymphoblastic leukemia (ALL), with decades of clinical validation across global multi-centre trials. The TxGNN model predicts it may be effective for Myeloid Leukemia — a mechanistically adjacent indication with historical precedent — supported by 29 clinical trials and 20 publications currently available. Evidence quality reaches L2, reflecting completed Phase 3/4 trials in APL maintenance and emerging Phase 1 data directly testing 6-MP in relapsed/refractory AML.

Quick Overview

Item	Content
Original Indication	Acute lymphoblastic leukemia (established global clinical use; no India regulatory authorisation on record)
Predicted New Indication	Myeloid Leukemia
TxGNN Prediction Score	99.94%
Evidence Level	L2
India Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Mercaptopurine belongs to the thiopurine class of antimetabolites. Once absorbed, it is converted by hypoxanthine-guanine phosphoribosyltransferase (HPRT) into 6-thioinosine monophosphate (TIMP) and subsequently into cytotoxic thioguanine nucleotides (TGNs). These TGNs are incorporated into both DNA and RNA, causing strand termination and triggering apoptosis in rapidly dividing cells. A secondary metabolic branch generates 6-methylmercaptopurine ribonucleotides (MMPRs), which inhibit phosphoribosyl pyrophosphate amidotransferase — the rate-limiting enzyme in de novo purine biosynthesis. This dual mechanism creates a broad-spectrum cytotoxic effect against any malignancy with high purine turnover, regardless of haematological lineage.

The mechanistic link between ALL and myeloid leukemia is direct: both diseases involve uncontrolled proliferation of leukemic blasts originating from haematopoietic progenitors, and both depend heavily on sustained nucleotide synthesis for DNA replication. Historically, 6-MP was a core component of AML induction regimens — most notably the Japanese BHAC-DM protocol (behenoyl cytarabine + daunorubicin + 6-MP), for which nationwide Phase 3 RCTs demonstrated complete remission rates exceeding 60%. In acute promyelocytic leukemia (APL), a biologically distinct AML subtype, 6-MP + methotrexate oral maintenance remains embedded in international standards (AIDA, PETHEMA LPA 2005, AIDA2000) as the two-year post-consolidation backbone.

More recently, the drug is regaining attention as a partner for novel agents: a Phase 1 trial (NCT05506332) is actively recruiting relapsed/refractory AML patients to test 6-MP + venetoclax, and a Phase 1/2 trial (NCT06199557) is investigating 6-MP + valproic acid for AML and high-risk MDS patients unfit for intensive chemotherapy. Together, these strands of evidence — historical RCT data, established APL maintenance protocols, and active early-phase trials — provide a coherent mechanistic and clinical rationale for TxGNN’s high-confidence prediction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05506332	Phase 1	Recruiting	10	ApoAML Trial: venetoclax + 6-MP combination in R/R AML; directly tests 6-MP efficacy in myeloid leukemia with a modern BCL-2 inhibitor backbone
NCT06199557	Phase 1/2	Recruiting	48	6-MP + valproic acid vs hydroxyurea + valproic acid for newly diagnosed AML or HR-MDS ineligible for standard therapy; targets a clinically urgent unmet need
NCT00003934	Phase 3	Completed	420	Untreated APL: randomised ATRA + anthracycline ± arsenic trioxide consolidation, followed by maintenance with tretinoin ± mercaptopurine + methotrexate; directly evaluated 6-MP’s maintenance contribution
NCT00408278	Phase 4	Completed	300	PETHEMA LPA 2005: risk-adapted ATRA + idarubicin induction; 6-MP + methotrexate oral maintenance for 2 years; confirmed tolerability and efficacy in a large, prospective APL cohort
NCT01064557	N/A	Unknown	1,068	AIDA guideline study (1993–2020) for APL ages >12 months; maintenance arm randomised between ATRA, methotrexate + 6-MP, or both in PCR-negative patients after consolidation
NCT00465933	Phase 4	Completed	N/A	APL AIDA with risk-stratified consolidation; ATRA + 6-MP + methotrexate maintenance; special evaluation of dose reduction in elderly patients (>70 years)
NCT00180128	Phase 4	Unknown	80	AIDA2000: APL risk-adapted therapy by age and WBC count; 2-year maintenance with 6-MP + methotrexate + ATRA as standard post-remission care
NCT00492856	Phase 3	Completed	105	S0521: Low/intermediate-risk APL — maintenance therapy versus observation; assessed the clinical necessity of sustained post-consolidation treatment
NCT00700544	Phase 3	Completed	330	GOELAMS SA-2002: elderly AML patients; ICL induction, then maintenance ± androgens; provided framing evidence for AML post-remission maintenance strategies in older adults
NCT02845232	N/A	Completed	214	Observational economic analysis of blood product transfusion requirements across AML treatment intensity levels; supports the case for low-toxicity maintenance options

Literature Evidence

PMID	Year	Type	Journal	Key Findings
10497848	1999	RCT	Int J Hematol	JALSG-AML92: daunorubicin + behenoyl cytarabine + 6-MP ± etoposide; no survival advantage from adding etoposide, confirming 6-MP’s role as a core component of Japanese AML induction
8174198	1994	RCT	Cancer Chemother Pharmacol	Nationwide Japan RCT (360 evaluable): BH-AC + daunorubicin + 6-MP vs BH-AC + aclarubicin + 6-MP; CR rates 63.7% vs 53.9%; established 6-MP as an AML combination-regimen standard
26425037	2015	Clinical Study	J Korean Med Sci	Oral 6-MP + weekly methotrexate for 2 years in transplant-ineligible AML patients after first CR; reported improved leukemia-free and overall survival versus no maintenance
9095207	1997	Phase 2	Cancer Invest	High-dose continuous IV 6-MP followed by intermediate-dose cytarabine during AML first remission in children; demonstrated feasibility of 6-MP intensification as consolidation component
1793832	1991	Clinical Study	Int J Hematol	41 adult AML patients: intensive behenoyl cytarabine + daunorubicin + 6-MP induction achieved 71% CR; multi-drug intensive regimen with 6-MP as purine backbone
24492035	2014	Review	Rinsho Ketsueki	Comprehensive review of AML and APL current therapy in Japan; contextualises the evolution of 6-MP-containing regimens and its residual role in APL maintenance
28835099	2017	Translational	Biomacromolecules	CD44-targeted glutathione-sensitive hyaluronic acid–6-MP prodrug (HA-GS-MP) for AML; enhanced intracellular delivery and superior cytotoxicity vs free 6-MP in AML cell lines
265178	1977	Clinical Study	Blood	Juvenile chronic myeloid leukemia: sequential subcutaneous cytarabine + oral 6-MP cycles achieved clinical and haematologic response in a disease previously considered unresponsive to chemotherapy
8383541	1993	Case Series	Ann Hematol	AML-M0 (minimally differentiated AML): review of 5 institutional cases and 63 published cases; 6-MP-containing combination regimens among the approaches evaluated
5220682	1966	Historical Study	Minnesota Med	One of the earliest reports of 6-MP + cyclophosphamide for AML; historical anchor establishing 6-MP’s multi-decade involvement in myeloid malignancy management

India Market Information

Mercaptopurine currently has no registered product authorisations in India. The drug is not marketed domestically. Any clinical use would rely on import or compounding under compassionate/investigational frameworks.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Antimetabolite (Thiopurine / Purine analog class)
Myelosuppression Risk	High — leucopenia, neutropenia, thrombocytopenia, and anaemia are expected, dose-limiting toxicities; severity is sharply amplified in patients with TPMT deficiency or NUDT15 R139C variant (especially relevant for Asian populations where NUDT15 R139C allele frequency is ~10%)
Emetogenicity Classification	Low
Monitoring Items	Complete blood count with differential (weekly during initiation; biweekly to monthly during stable maintenance), liver function tests (ALT, AST, bilirubin — 6-MP hepatotoxicity via MMPN accumulation), renal function; pre-treatment TPMT and NUDT15 genotyping is a clinical necessity — dose must be reduced by 50–90% in intermediate/poor metabolisers
Handling Protection	Must be handled under cytotoxic drug handling regulations; do not crush or split tablets without appropriate PPE; pregnant healthcare workers should not handle the drug

Safety Considerations

Drug Interactions (296 total interactions identified; key interactions listed below):

Interacting Drug	Level	Clinical Note
Mesalazine	Moderate	Aminosalicylates inhibit TPMT activity, raising TGN levels and myelotoxicity risk; dose reduction of 6-MP required if co-administered
Sulfasalazine	Moderate	Same TPMT-inhibition mechanism as mesalazine; frequent co-medication in IBD patients also treated with thiopurines
Balsalazide	Moderate	Same class; caution warranted in overlap IBD/haematology patients
Olsalazine	Moderate	Same class
Naltrexone	Moderate	Low-dose naltrexone may interact via immunomodulatory pathways; mechanism not fully characterised

Please refer to the package insert for complete warnings, contraindications, and the full interaction list.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: 6-MP is already embedded as a standard post-remission maintenance agent in APL (an AML subtype), validated by multiple completed Phase 3/4 international trials and longstanding inclusion in AIDA-based protocols. A 2015 prospective study further demonstrated survival benefit for 6-MP oral maintenance in non-APL AML patients ineligible for transplantation. Two currently active early-phase trials (NCT05506332, NCT06199557) are directly testing 6-MP in broader AML settings, confirming sustained clinical interest. The TxGNN score of 99.94% and L2 evidence rating align with this substantial but largely AML-subtype-specific track record.

To proceed, the following is needed:

Pharmacogenomic screening: Pre-treatment TPMT and NUDT15 genotyping for all patients; establish a local dosing adjustment protocol adapted to Indian population allele frequencies
Regulatory pathway: Initiate CDSCO import/marketing authorisation process — no approved India formulation currently exists
Indication-specific protocol design: Distinguish APL maintenance context (low-intensity, long-term 6-MP + MTX) from broader AML contexts (higher-intensity or novel-combination settings); tailor dosing and monitoring accordingly
Mechanistic data gap (DG002): Retrieve full DrugBank MOA and pharmacodynamics data to complete the mechanistic dossier
Safety data gap (DG001): Obtain TFDA/reference label package insert to formalise contraindication and warning documentation for the Indian regulatory submission
Prospective registry or Phase 2 study: Consider an India-specific study of 6-MP oral maintenance in transplant-ineligible AML patients, given the unmet need and preliminary supportive evidence

Disclaimer: This report is for research reference purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.